Amgen-话题@MedSci - 梅斯（MedSci）

#Amgen#

10篇内容 | 1201人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1746577, encodeId=65711e46577f1, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, objectType=article, longId=168697, objectId=cf5816869ebe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf5816869ebe, replyNumber=0, likeNumber=80, createdTime=2019-11-06, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf5816869ebe, moduleTitle=2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cf5816869ebe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746576, encodeId=8dc91e46576dc, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, objectType=article, longId=167693, objectId=bf9916e693b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf9916e693b0, replyNumber=0, likeNumber=75, createdTime=2020-02-24, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf9916e693b0, moduleTitle=Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bf9916e693b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746574, encodeId=92901e465743e, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=Amgen在美国推出骨质疏松症药物Evenity，年度定价为21900美元, objectType=article, longId=164437, objectId=1e9416443ec1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e9416443ec1, replyNumber=0, likeNumber=65, createdTime=2020-01-18, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e9416443ec1, moduleTitle=Amgen在美国推出骨质疏松症药物Evenity，年度定价为21900美元, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=1e9416443ec1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746575, encodeId=4ded1e465751b, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据, objectType=article, longId=167644, objectId=60cf16e64489, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60cf16e64489, replyNumber=0, likeNumber=70, createdTime=2020-05-17, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60cf16e64489, moduleTitle=2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=60cf16e64489)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746573, encodeId=c5821e46573ae, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症, objectType=article, longId=155933, objectId=5a611559332d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a611559332d, replyNumber=0, likeNumber=91, createdTime=2019-06-28, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a611559332d, moduleTitle=FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=5a611559332d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746570, encodeId=b93a1e4657029, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, objectType=article, longId=136728, objectId=2a86136e2899, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a86136e2899, replyNumber=0, likeNumber=66, createdTime=2018-11-05, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a86136e2899, moduleTitle=Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2a86136e2899)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746569, encodeId=456b1e46569ca, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=Amgen/Novartis偏头痛单克隆抗体Aimovig临床三期实验成功, objectType=article, longId=135848, objectId=d1ca135848dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1ca135848dd, replyNumber=0, likeNumber=123, createdTime=2018-12-19, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1ca135848dd, moduleTitle=Amgen/Novartis偏头痛单克隆抗体Aimovig临床三期实验成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d1ca135848dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746571, encodeId=eb221e4657118, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=美国食品和药物管理局通过Amgen的Prolia解决糖皮质激素骨质疏松症问题, objectType=article, longId=138997, objectId=b8cb13899ea0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b8cb13899ea0, replyNumber=0, likeNumber=62, createdTime=2018-06-29, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b8cb13899ea0, moduleTitle=美国食品和药物管理局通过Amgen的Prolia解决糖皮质激素骨质疏松症问题, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b8cb13899ea0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746572, encodeId=d3b21e46572b2, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, objectType=article, longId=145379, objectId=2d8b1453e9a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d8b1453e9a0, replyNumber=0, likeNumber=68, createdTime=2018-08-24, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d8b1453e9a0, moduleTitle=EMA支持批准Amgen的Neulasta的第一个生物仿制药版本, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d8b1453e9a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1746568, encodeId=0d961e465687a, content=<a href='/topic/show?id=7344241edc' target=_blank style='color:#2F92EE;'>#Amgen#</a>, objectTitle=安进（Amgen）实验性抗体药物AMG145 Ib期研究取得惊人数据, objectType=article, longId=5392, objectId=34ee5392fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=34ee5392fc, replyNumber=0, likeNumber=72, createdTime=2012-11-23, rootId=0, userName=cenghis, userId=8e1735781236, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=34ee5392fc, moduleTitle=安进（Amgen）实验性抗体药物AMG145 Ib期研究取得惊人数据, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=34ee5392fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Amgen

2020-05-29

cenghis (审核中...)

前往app查看评论内容

#Amgen#

2019 EHA：Amgen双特异性抗体Blincyto治疗白血病的五年生存数据喜人

2019-11-06

cenghis (审核中...)

前往app查看评论内容

#Amgen#

Amgen的AMG 510在KRAS突变的非小细胞肺癌I期临床实现突破

2020-02-24

cenghis (审核中...)

前往app查看评论内容

#Amgen#

Amgen在美国推出骨质疏松症药物Evenity，年度定价为21900美元

2020-01-18

cenghis (审核中...)

前往app查看评论内容

#Amgen#

2019 ASCO：Amgen的双特异性抗体BiTE疗法展示出阳性数据

2020-05-17

cenghis (审核中...)

前往app查看评论内容

#Amgen#

FDA批准Amgen的Nplate治疗儿科免疫性血小板减少症

2019-06-28

cenghis (审核中...)

前往app查看评论内容

#Amgen#

Amgen获得CHMP正面意见：denosumab可用于糖皮质激素诱导的骨质疏松症患者

2018-11-05

cenghis (审核中...)

前往app查看评论内容

#Amgen#

Amgen/Novartis偏头痛单克隆抗体Aimovig临床三期实验成功

2018-12-19

cenghis (审核中...)

前往app查看评论内容

#Amgen#

美国食品和药物管理局通过Amgen的Prolia解决糖皮质激素骨质疏松症问题

2018-06-29

cenghis (审核中...)

前往app查看评论内容

#Amgen#

EMA支持批准Amgen的Neulasta的第一个生物仿制药版本

2018-08-24

cenghis (审核中...)

前往app查看评论内容

#Amgen#

安进（Amgen）实验性抗体药物AMG145 Ib期研究取得惊人数据

2012-11-23

科室
- - 订阅+
  - 更多科室
工具
服务